Taken together, our study suggested that the molecular mechanisms of REP1 in regulating mTOR and subsequent lysosomal degradation pathways, as well as targeting autophagy, might be possible therapeutic options for cancer patients with high expression of REP1 levels. The gene discussed is CHM; the disease is cancer.